GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Retained Earnings

Everest Medicines (HKSE:01952) Retained Earnings : HK$-10,738.5 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Everest Medicines's retained earnings for the quarter that ended in Dec. 2024 was HK$-10,738.5 Mil.

Everest Medicines's quarterly retained earnings declined from Dec. 2023 (HK$-9,862.0 Mil) to Jun. 2024 (HK$-10,387.5 Mil) and declined from Jun. 2024 (HK$-10,387.5 Mil) to Dec. 2024 (HK$-10,738.5 Mil).

Everest Medicines's annual retained earnings declined from Dec. 2022 (HK$-9,125.8 Mil) to Dec. 2023 (HK$-9,862.0 Mil) and declined from Dec. 2023 (HK$-9,862.0 Mil) to Dec. 2024 (HK$-10,738.5 Mil).


Everest Medicines Retained Earnings Historical Data

The historical data trend for Everest Medicines's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Retained Earnings Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial -8,198.47 -9,703.58 -9,125.81 -9,862.04 -10,738.49

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,125.81 -9,401.73 -9,862.04 -10,387.45 -10,738.49

Everest Medicines Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Everest Medicines  (HKSE:01952) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p. 2201 Interest of corporation controlled by you
Tf Capital Iv Ltd. 2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd. 2501 Other
C-bridge Healthcare Fund Gp Ii, L.p. 2501 Other
C-bridge Healthcare Fund Ii, L.p. 2501 Other
C-bridge Investment Everest Limited 2501 Other
Tf Capital Ii Ltd. 2501 Other
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Fu Wei 2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse

Everest Medicines Headlines

No Headlines